US Image-Guided Biopsy Market Trends 2025-2033: MRI and CT-Guided Biopsies Experience High Adoption in Hospitals and Ambulatory Centers

The Global Image-Guided Biopsy Market was valued at US$ 1.4 billion in 2024 and is projected to reach US$ 2.05 billion by 2031, growing at a CAGR of 5.6% during the forecast period (2025-2031). This growth is fueled by the increasing incidence of cancer and chronic diseases, along with rising demand for minimally invasive diagnostic procedures that enable faster, more accurate tissue sampling.

The market is at the forefront of diagnostics thanks to ongoing advancements in needle guidance systems and imaging modalities like MRI, CT, and ultrasound. Image-guided biopsy is a crucial enabler in precision medicine as providers, hospitals, and diagnostic centers embrace these cutting-edge technologies to shorten procedure times, improve patient comfort, and improve results.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/image-guided-biopsy-market?sai-v

The image-guided biopsy market involves minimally invasive procedures that use imaging technologies like ultrasound, CT, or MRI to precisely locate and extract tissue samples for accurate disease diagnosis.

Key Developments

✅ June 2025 (United States): GE HealthCare introduced its next-generation image-guided biopsy platform integrating AI-assisted lesion targeting and real-time 3D visualization. The system enhances accuracy in breast and lung biopsies, supporting precision diagnostics across U.S. hospitals and imaging centers.

✅ April 2025 (United States): Hologic Inc. launched a new vacuum-assisted breast biopsy system compatible with advanced MRI scanners, enabling faster and minimally invasive tissue sampling. The upgrade focuses on improving diagnostic yield and patient comfort in outpatient settings.

✅ May 2025 (Japan): Canon Medical Systems developed a high-resolution ultrasound-guided biopsy module equipped with real-time needle tracking and automated lesion depth assessment. The technology is being adopted by major Japanese medical institutions for oncology and liver diagnostics.

✅ February 2025 (Japan):Hitachi Ltd. collaborated with a domestic healthcare AI startup to integrate deep learning algorithms into its image-guided biopsy systems, enhancing lesion differentiation and decision support for radiologists.

Mergers & Acquisitions

✅ March 2025 (United Siemens Healthineers acquired a U.S.-based medical imaging software firm specializing in biopsy workflow automation. The acquisition strengthens Siemens' precision imaging and digital health portfolio.

✅ January 2025 (Japan): A leading Japanese medical technology company acquired a regional imaging device manufacturer to expand its biopsy device line and strengthen its local supply chain capabilities for minimally invasive diagnostics.

Market Outlook

"Image-guided biopsy systems are transforming early cancer detection with AI precision and minimally invasive design."

◆ United States: Strong FDA approvals for next-gen MRI and ultrasound-guided systems, combined with AI integration, are driving rapid adoption across diagnostic and oncology centers.

◆ Japan: The market is advancing with innovations in AI-powered ultrasound and CT-guided biopsy technologies, supported by hospital modernization and government focus on early cancer detection.

◆ Globally, the market is poised for solid growth through 2030, driven by digital imaging advancements, AI-assisted accuracy, and increased preference for minimally invasive diagnostic procedures.

Key Players:

Koninklijke Philips N.V. | Siemens Healthcare GmbH | GE Healthcare | Brainlab | Medtronic

Key Highlights:

• Koninklijke Philips N.V. - Reported USD 19.2 billion in 2024, leading in medical imaging, diagnostics, and connected care.
• Siemens Healthcare GmbH - Generated USD 23.5 billion, focusing on advanced imaging systems and digital health solutions.
• GE Healthcare - Achieved USD 19.6 billion, expanding its AI-enabled diagnostics and precision health technologies.
• Brainlab - Estimated USD 400 million, specializing in neurosurgery, oncology, and digital operating room solutions.
• Medtronic - Recorded USD 32.3 billion, driving innovation in minimally invasive surgery and medical technologies.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=image-guided-biopsy-market?sai-v
(Purchase 2 or more reports and get 50% discount.)

Market Drivers & Growth:

The increasing incidence of cancer and chronic diseases is driving demand for "image-guided biopsy" procedures, which enable earlier and more accurate diagnoses.

Growing adoption of advanced imaging technologies such as MRI, CT, and ultrasound for real-time procedural guidance is improving precision and reducing patient risk.

A shift toward minimally invasive diagnostic methods is replacing more invasive surgical biopsies, offering shorter recovery times and lower healthcare costs.

Innovations such as AI-powered imaging systems and robotic-assisted biopsy devices are enhancing accuracy and operational efficiency.

The global market was valued at approximately USD 1.4 billion in 2024 and is projected to grow to around USD 2.05 billion by 2031, according to one estimate.

Regional Insights:

United States: Dominates the market thanks to high cancer screening rates, widespread deployment of advanced imaging systems, and well-established reimbursement frameworks.

Japan: Shows strong growth driven by rising demand for ultrasound- and MRI-guided biopsies, coupled with an aging population and technological innovation in medical diagnostics.

Europe: Maintains a solid market position, supported by national cancer screening programs and strong device manufacturing hubs in countries like Germany, France and the United Kingdom.

Asia-Pacific (Excluding Japan): Among the fastest-growing regions, led by China and India, where healthcare modernization and increased access to diagnostic services are boosting uptake of image-guided biopsy system

Key Segments:

➥ By Technology:
X-Ray, Ultrasound, Mammography, CT, MRI, Others
Each segment includes introduction, market size analysis (US$ million, 2020-2029), year-on-year growth analysis (2021-2029), and market attractiveness index.

➥ By Process:
Fine Needle, Core Needle, Vacuum-Assisted Biopsy, Others
Each segment includes introduction, market size analysis (US$ million, 2020-2029), year-on-year growth analysis (2021-2029), and market attractiveness index.

➥ By Indication:
Cancer, Liver Disease, Kidney Disease, Infectious Diseases, Others
Each segment includes introduction, market size analysis (US$ million, 2020-2029), year-on-year growth analysis (2021-2029), and market attractiveness index.

➥ By End User:
Hospitals, Diagnostic Centers, Ambulatory Surgery Centers, Research Institutes, Others
Each segment includes introduction, market size analysis (US$ million, 2020-2029), year-on-year growth analysis (2021-2029), and market attractiveness index.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/image-guided-biopsy-market?sai-v

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.